Immatics (IMTX)

Immatics (IMTX) Stock Price & Analysis


IMTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$5.90 - $13.60
Previous Close$10.09
Average Volume (3M)426.58K
Market Cap
Enterprise Value$639.65M
Total Cash (Recent Filing)€148.52M
Total Debt (Recent Filing)€14.56M
Price to Earnings (P/E)20.9
Aug 08, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding76,670,000
10 Day Avg. Volume452,264
30 Day Avg. Volume426,577
Standard Deviation0.15
Financial Highlights & Ratios
Price to Book (P/B)3.68
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside80.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5




What was Immatics’s price range in the past 12 months?
Immatics lowest stock price was $5.90 and its highest was $13.60 in the past 12 months.
    What is Immatics’s market cap?
    Currently, no data Available
    When is Immatics’s upcoming earnings report date?
    Immatics’s upcoming earnings report date is Aug 08, 2023 which is in 61 days.
      How were Immatics’s earnings last quarter?
      Immatics released its earnings results on May 16, 2023. The company reported -$0.278 earnings per share for the quarter, beating the consensus estimate of -$0.291 by $0.013.
        Is Immatics overvalued?
        According to Wall Street analysts Immatics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Immatics pay dividends?
          Immatics does not currently pay dividends.
          What is Immatics’s EPS estimate?
          Immatics’s EPS estimate is -$0.28.
            How many shares outstanding does Immatics have?
            Immatics has 76,670,700 shares outstanding.
              What happened to Immatics’s price movement after its last earnings report?
              Immatics reported an EPS of -$0.278 in its last earnings report, beating expectations of -$0.291. Following the earnings report the stock price went down -1.992%.
                Which hedge fund is a major shareholder of Immatics?
                Among the largest hedge funds holding Immatics’s share is Baker Bros Advisors LP. It holds Immatics’s shares valued at 36M.


                  Immatics Stock Smart Score

                  The Immatics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description


                  Immatics NV is engaged in discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.


                  Top 5 ETFs holding IMTX

                  Currently, no data available
                  Please return soon. This page is being updated.
                  Up to five ETFs with an Outperform Smart Score that hold IMTX. The ETFs are listed according to market value of IMTX within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  BioNTech SE
                  Formycon AG

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis